A large real-world study shows lower all-cause mortality and some cardiovascular outcomes with combination therapy; other outcomes lack statistical precision.

Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.

The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s ...

A study published in Pediatrics journal revealed that the use of GLP-1 receptor agonists (GLP-1 RAs) in youth aged 10–17 ...

Researchers say knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.

GLP-1RA initiation in type 1 diabetes associated with lower risks of major cardiovascular events and end-stage kidney disease. Patients using GLP-1RAs more likely to achieve clinically meaningful ...

The incidence of colorectal cancer among users of GLP-1RAs was approximately 36% lower than that observed among aspirin users. The use of GLP-1 receptor antagonist (GLP-1RA) therapy has led to a ...

New real-world evidence suggests that staying on GLP-1 therapy may be critical for sustaining cardiovascular protection, while even short interruptions could diminish long-term benefits in people with ...

About The Study: In this large cohort of adults with overweight or obesity without diabetes, fewer than 1 in 4 patients remained on any glucagon-like peptide-1 receptor agonist (GLP-1RA) after 12 ...